Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q1 2016 · 10-Q
Revenue$120.00K$120.00K−5.5% vs Q1 2015 Net Income-$10.26M-$10.26MN/M vs Q1 2015 EPS Diluted-$0.36-$0.36N/M vs Q1 2015 Operating Income-$10,458,648N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
Free Cash Flowderived-$7,267,730N/M Margins · derivedOperating margin-8715.5%−4898.4 pt vs Q1 2015
Net margin-8552.1%−2903.0 pt vs Q1 2015
ended Mar 31, 2016 · filed May 10, 2016 · 40 d after period end